Biotron Limited (AU:BIT) has released an update.
Biotron Limited reported positive outcomes from their Phase 2 HIV-1 clinical trial with their lead antiviral drug BIT225, achieving all primary objectives and demonstrating safety and efficacy alongside standard antiretroviral therapy. The company is also progressing with post-clinical analyses of additional Phase 2 trials for BIT225 in treating COVID-19 and is optimistic about reporting further results in the next quarter. These developments could potentially attract pharmaceutical partners and meet currently unmet medical needs.
For further insights into AU:BIT stock, check out TipRanks’ Stock Analysis page.
